This genetic heterogeneity increases the risk of selecting treatment-resistant or target-negative subclones following therapeutic exposure with targeted agents, as can be seen with development of BCR-ABL1 kinase domain mutations in CML [11]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.